Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by the increase in the triglycerides (TGs) level due to reduction in the LPL, which is an enzyme that helps to break down chylomicrons (CMs) in the body. The reduction in the LPL leads to the buildup of CMs which are rich in the triglycerides.
It is also known as lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, endogenous hypertriglyceridemia, familial fat-induced hypertriglyceridemia, familial hyperchylomicronemia, and familial LPL deficiency, hyperlipidemia Type I (fredrickson), hyperlipoproteinemia Type IA, lipase D deficiency, and Burger-Grutz syndrome. The diagnosis is mainly supported by the presence of markedly elevated TG concentrations and CM, the latter of which is normally rapidly cleared from the plasma following a meal.
The current treatment involves the restriction in the dietary fat intake allied with traditional TG-lowering agents like fibrates, statins, and niacin’s. However, there is no US Food and Drug Administration (FDA) approved drug for the treatment of FCS, but in May 2019, Waylivra (volanesorsen) was conditionally approved by European Commission (EC) for the treatment of FCS.
Nearly 70% of patients reported that FCS interfered significantly with their self-worth, emotional well-being, sleep, and mental functioning. The dietary restriction of fat intake and traditional TG-lowering agents are not so efficacious in these patients.
The Familial Chylomicronemia Syndrome market report covers emerging drugs, current treatment practices, Familial Chylomicronemia Syndrome market share of the individual therapies, current and forecasted Familial Chylomicronemia Syndrome Market Size from 2017 to 2030 segmented by seven major markets.
The report also provides detailed current Familial Chylomicronemia Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Familial Chylomicronemia Syndrome Market Key Facts
The total prevalent population of FCS in the 7MM was assessed to be 5,801 in 2017, and are expected to increase during the study period.
The United States had the highest market size of FCS in 2017, which accounts for approximately 30% of the total market.
Among the European 5 countries, Germany had the highest prevalent population of FCS, followed by France and the United Kingdom (in 2017)
Visit For Sample Pages:
Key Benefits of Familial Chylomicronemia Syndrome Market Report
Familial Chylomicronemia Syndrome market report provides an in-depth analysis of Familial Chylomicronemia Syndrome Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Familial Chylomicronemia Syndrome market report will help in developing business strategies by understanding the Familial Chylomicronemia Syndrome Market trends & developments, key players and future market competition that will shape and drive the Familial Chylomicronemia Syndrome market in the upcoming years.
The Familial Chylomicronemia Syndrome market report covers Familial Chylomicronemia Syndrome current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Familial Chylomicronemia Syndrome market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Familial Chylomicronemia Syndrome market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Familial Chylomicronemia Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Familial Chylomicronemia Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Familial Chylomicronemia Syndrome Epidemiology
The Familial Chylomicronemia Syndrome epidemiology section covers insights about historical and current Familial Chylomicronemia Syndrome patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The Familial Chylomicronemia Syndrome Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched in the market during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Some of the Emerging therapies in Familial Chylomicronemia Syndrome (FCS) Market include AKCEA-ANGPTL3-LRx (ISIS 703802), AKCEA-APOCIII-LRx, ARO-APOC3 and others. Key players, such as Arrowhead, Akcea Therapeutics, Ionis Pharmaceuticals, Amryt Pharma, and others are involved in developing drugs for Familial Chylomicronemia Syndrome (FCS.
Table of Contents
1. Key Insights
2. Executive Summary
3. Familial Chylomicronemia Syndrome Competitive Intelligence Analysis
4. Familial Chylomicronemia Syndrome Market Overview at a Glance
5. Familial Chylomicronemia Syndrome Disease Background and Overview
6. Familial Chylomicronemia Syndrome Patient Journey
7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population
8. Familial Chylomicronemia Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Familial Chylomicronemia Syndrome Unmet Needs
10. Key Endpoints of Familial Chylomicronemia Syndrome Treatment
11. Familial Chylomicronemia Syndrome Marketed Products
12. Familial Chylomicronemia Syndrome Emerging Therapies
13. Familial Chylomicronemia Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Familial Chylomicronemia Syndrome Market Outlook (7 major markets)
16. Familial Chylomicronemia Syndrome Access and Reimbursement Overview
17. KOL Views on the Familial Chylomicronemia Syndrome Market.
18. Familial Chylomicronemia Syndrome Market Drivers
19. Familial Chylomicronemia Syndrome Market Barriers
21. DelveInsight Capabilities
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Familial Chylomicronemia Syndrome (FCS) Epidemiology Forecast to 2030
DelveInsight’s ‘Familial Chylomicronemia Syndrome (FCS) Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted FCS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States